Make an enquiry
Refer a patient
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2018-11-04T00:00:00.000+08:00

[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
The Lancet Oncology, volume: Jun; 19(6), pages 825-833
https://pubmed.ncbi.nlm.nih.gov/29752180/
Theranostics
Written by Michael S Hofman; John Violet; Rodney J Hicks; Justin Ferdinandus; Sue Ping Thang; Tim Akhurst; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Declan G Murphy; Peter Eu; Price Jackson; Mark Scalzo; Scott G Williams; Shahneen Sandhu
Michael S Hofman; John Violet; Rodney J Hicks; Justin Ferdinandus; Sue Ping Thang; Tim Akhurst; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Declan G Murphy; Peter Eu; Price Jackson; Mark Scalzo; Scott G Williams; Shahneen Sandhu:::

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.